argenx NV ADR (ARGX)vsCatalyst Pharmaceuticals Inc (CPRX)
ARGX
argenx NV ADR
$782.17
-0.65%
HEALTHCARE · Cap: $49.20B
CPRX
Catalyst Pharmaceuticals Inc
$31.15
-0.05%
HEALTHCARE · Cap: $3.81B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 705% more annual revenue ($4.74B vs $588.99M). CPRX leads profitability with a 36.4% profit margin vs 31.4%. CPRX trades at a lower P/E of 18.6x. ARGX earns a higher WallStSmart Score of 75/100 (B).
ARGX
Strong Buy75
out of 100
Grade: B
CPRX
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.4%
Fair Value
$2344.11
Current Price
$782.17
$1561.94 discount
Intrinsic value data unavailable for CPRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Every $100 of equity generates 20 in profit
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 40.5%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.4x book value
Weak financial health signals
Earnings declined 6.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : CPRX
The strongest argument for CPRX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 36.4% and operating margin at 40.5%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CPRX
The primary concerns for CPRX are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CPRX is a mature play — different risk/reward profiles.
CPRX carries more volatility with a beta of 0.72 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (75/100 vs 57/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Catalyst Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?